Wednesday, July 15, 2026

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

Is Canada’s Shift to China a Sign of U.S. Isolation? Discover the Impact of Trump’s Tariffs

Biden's strategy post-Ukraine invasion contained Russia and checked China, while Trump's policies strained U.S. alliances and empowered China.

How Celltrion is Tackling U.S. Tariff Risks with New Production Facility in 2026

Celltrion addresses tariff risks by acquiring a U.S. facility, ensuring product supply and implementing strategies to mitigate uncertainties.

Tag: Zaqbo

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Onconic Therapeutics Expands Zaqbo Development in China With Phase 3 Trial for H. pylori Eradication

Onconic Therapeutics' Zaqbo enters Phase 3 trials in China for H. pylori eradication, with strong revenue growth reported.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.